The Society for Cardiovascular Angiography and Interventions’ (SCAI) 2015 scientific session will flash some big names on its marque this year, with PROMETHEUS, ORBIT II and other trials scheduled to make an appearance.

The annual SCAI conference for interventional cardiologists is set to take place May 6-9 in San Diego. The event will include six late-breaking clinical trials along with lectures, educational presentations, training programs and a return of the Cath Lab Boot Camp. The organizers also added a new feature, “State of the Art Technologies,” to give attendees a glimpse of emerging devices and other innovations that could impact future practice.

The late-breaking clinical trials will be held May 7 and 8. Here is the schedule:

May 7

• Orbital Atherectomy Treatment of Severely Calcified Coronary Lesions: Two-Year Results of the ORBIT II Trial and Long-Term Economic Analysis
• Ticagrelor vs. Clopidogrel in Troponin-negative Patients with Acute Coronary Syndrome Undergoing Ad Hoc Percutaneous Coronary Intervention: Results of a Prospective, Randomized, Multicenter Pharmacodynamic Study
• Impact of Combined Lipid Lowering with Calcium Channel Antagonist-based Blood Pressure Control on Coronary Plaque Regression: MILLION Study

May 8

• OUTSIDE START Cilostazol Bridging Study: 8-Year Experience with Outpatient Cilostazol Bridging in High Stent Thrombosis Risk Paclitaxel Drug-Eluting Stents in Patients Having Surgery During the Proven At-Risk Period
• 90 Day Effectiveness and Safety of Prasugrel vs. Clopidogrel as Used in Clinical Practice in Patients With ACS Undergoing PCI: Initial Findings from the PROMETHEUS Study
• Impact of an Integrated Treatment Algorithm Based on Platelet Function Testing and Clinical Risk Assessment: Results of the TRIAGE study